Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 181 to 195 of 300 results for breast cancer

  1. AlignRT for intracranial stereotactic radiosurgery (MIB147)

    NICE has developed a medtech innovation briefing (MIB) on AlignRT for intracranial stereotactic radiosurgery .

    Medtech innovation briefing
    Published
    16 May 2018

  2. Oral paclitaxel with encequidar for treating advanced breast cancer [ID5111]

    In development [GID-TA11022] Expected publication date: TBC

    Technology appraisal guidance
    In development

  3. Tucatinib with trastuzumab emtansine for treating HER2-positive unresectable or advanced breast cancer after a taxane, trastuzumab or both together TS ID 11781

    Awaiting development [GID-TA11110] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  4. Sunitinib in combination with a taxane for the first line treatment of advanced and/or metastatic breast cancer [ID58]

    Discontinued [GID-TAG391]

    Technology appraisal guidance
    Discontinued

  5. Bevacizumab in combination with chemotherapy for the second line treatment of HER2 negative metastatic breast cancer [ID488]

    Discontinued [GID-TAG432]

    Technology appraisal guidance
    Discontinued

  6. Trastuzumab duocarmazine for treating HER2-positive unresectable metastatic breast cancer after 2 or more anti-HER2 treatments or after trastuzumab emtansine [ID6318]

    Awaiting development [GID-TA11339] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  7. Veliparib in combination for treating BRCA-positive, HER2-negative breast advanced cancer [ID1404]

    Discontinued [GID-TA10327]

    Technology appraisal guidance
    Discontinued

  8. Recognition of lung cancer

    The section of the NICE impact lung cancer report looking at how lung cancer is detected.

  9. Everolimus with exemestane for treating HER2-negative hormone-receptor-positive breast cancer after endocrine therapy [ID965]

    Discontinued [GID-TA10028]

    Technology appraisal guidance
    Discontinued

  10. Intensity modulated radiotherapy for breast cancer [ID16]

    Discontinued [GID-TAG390]

    Technology appraisal guidance
    Discontinued

  11. Abemaciclib monotherapy for treating advanced hormone-receptor positive, HER2-negative breast cancer after endocrine therapy and chemotherapy [ID1347]

    Discontinued [GID-TA10264]

    Technology appraisal guidance
    Discontinued

  12. Board, executive team and senior leaders interests register

    specialty adviser for medical oncology.Trustee 'It's in the Bag' testicular cancer charity.Member of Sciensus medical advisory...

  13. Board, executive team and senior leaders interests register

    specialty adviser for medical oncology.Trustee 'It's in the Bag' testicular cancer charity.Member of Sciensus medical advisory...

  14. Board, executive team and senior leaders interests register

    specialty adviser for medical oncology.Trustee 'It's in the Bag' testicular cancer charity.Member of Sciensus medical advisory...

  15. Lapatinib in combination with paclitaxel for the first-line treatment of metastatic breast cancer which over-expresses ErbB2 (HER2) receptor [ID517]

    Discontinued [GID-TAG436]

    Technology appraisal guidance
    Discontinued